Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease.
Akash VirupakshaiahVinícius Andreoli SchoepsJonathan RaceMichael WaltzSiefaddeen SharayahZahra NasrCarson E MoseleyScott S ZamvilCristina GaudiosoAllison SchuetteTheron Charles CasperJohn RoseEoin Patrick FlanaganMoses RodriguezJan-Mendelt TillemaTanuja ChitinisMark P GormanJennifer S GravesLeslie A BensonMary RenselAaron W AbramsLauren B KruppTimothy E LotzeGregory AaenYolanda WheelerTeri SchreinerAmy WaldmanJanet ChongSoe MarEmmanuelle WaubantPublished in: Journal of neurology, neurosurgery, and psychiatry (2024)
Sex and ethnicity are associated with relapsing MOGAD. Use of rituximab or IVIG therapy shortly after onset is associated with a lower risk of the second event. Preventive treatment after a first event could be considered for those with a higher relapse risk.